# Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database

> **NCT01381510** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 54459 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** 5-alpha Reductase Inhibitor (5ARI)

## Key facts

- **NCT ID:** NCT01381510
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 54459 (ACTUAL)
- **Last updated:** 2012-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381510, "Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01381510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*